Secretory immunoglobulin A:: from mucosal protection to vaccine development

被引:34
作者
Corthésy, B [1 ]
Spertini, F [1 ]
机构
[1] CHU Vaudois, Div Immunol & Allergie, CH-1011 Lausanne, Switzerland
关键词
mucosal immunity; recombinant immunoglobulins; secretory IgA; vaccine;
D O I
10.1515/BC.1999.160
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immune responses taking place in mucosal tissues are typified by secretory immunoglobulin A (S-IgA) molecules, which are assembled from proteins expressed in two cell lineages. The heavy and light chains as well as the J chain are produced in plasma cells, whereas the secretory component (SC) is associated to the immunoglobulin complex during transcytosis across the epithelial layer. S-IgA antibodies represent the predominant immunoglobulin class in external secretions, and the best defined entity providing specific immune protection for mucosal surfaces by blocking attachment of bacteria and viruses, S-IgA constitutes greater than 80% of all antibodies produced in mucosa-associated lymphoid tissues in humans. The existence of a common mucosal immune system permits immunization on one mucosal surface to induce secretion of antigen-specific S-IgA at distant sites. In addition, S-IgA antibodies not only function in external secretions, but also exert their antimicrobial properties within the epithelial cell during transport across the epithelium. Passive mucosal delivery of monoclonal IgA molecules neutralizes pathogens responsible for gastrointestinal and respiratory infections. Mucosal and systemic immunity can be achieved by orally administered recombinant S-IgA molecules carrying a protective bacterial epitope within the SC polypeptide primary sequence.
引用
收藏
页码:1251 / 1262
页数:12
相关论文
共 128 条
[1]  
ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393
[2]  
[Anonymous], FORESTS GLOBAL CHANG
[3]   ANALYSIS OF THE ROLES OF ANTILIPOPOLYSACCHARIDE AND ANTICHOLERA TOXIN IMMUNOGLOBULIN A (IGA) ANTIBODIES IN PROTECTION AGAINST VIBRIO-CHOLERAE AND CHOLERA-TOXIN BY USE OF MONOCLONAL IGA ANTIBODIES IN-VIVO [J].
APTER, FM ;
MICHETTI, P ;
WINNER, LS ;
MACK, JA ;
MEKALANOS, JJ ;
NEUTRA, MR .
INFECTION AND IMMUNITY, 1993, 61 (12) :5279-5285
[4]   REVERSAL OF THE IMMUNOSENESCENT PHENOTYPE BY DEHYDROEPIANDROSTERONE - HORMONE-TREATMENT PROVIDES AN ADJUVANT EFFECT ON THE IMMUNIZATION OF AGED MICE WITH RECOMBINANT HEPATITIS-B SURFACE-ANTIGEN [J].
ARANEO, BA ;
WOODS, ML ;
DAYNES, RA .
JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (04) :830-840
[5]  
Atkin JD, 1996, J IMMUNOL, V157, P156
[6]  
BAKOS MA, 1991, J IMMUNOL, V147, P3419
[7]  
BEAGLEY KW, 1992, GASTROENTEROL CLIN N, V21, P347
[8]   In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells [J].
Berdoz, J ;
Blanc, CT ;
Reinhardt, M ;
Kraehenbuhl, JP ;
Corthésy, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (06) :3029-3034
[9]  
BERDOZ J, 1995, PCR METH APPL, V4, P256
[10]   INTERACTION OF A SALIVARY MUCIN-SECRETORY IMMUNOGLOBULIN-A COMPLEX WITH MUCOSAL PATHOGENS [J].
BIESBROCK, AR ;
REDDY, MS ;
LEVINE, MJ .
INFECTION AND IMMUNITY, 1991, 59 (10) :3492-3497